Multicentre REtrospective StuDy of Treatment and OUtComes in STEMI Patients in Fujian Province

ST-segment Elevation Myocardial Infarction Clinical Trial

— REDUCTION  

Official title:

Multicentre REtrospective StuDy of Treatment and OUtComes in ST-elevatION Myocardial Infarction(STEMI) Patients in Fujian Province

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03763968
• Other study ID #: YGuo
• Status: Completed
• Start date: January 1, 2014
• Est. completion date: December 31, 2018

Study information

• Verified date: January 2019
• Source: Fujian Provincial Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a multicentre observational study planned to gather follow up data for a period of 1 year in order to understand the treatments and outcomes of ST-segment elevation myocardial infarction(STEMI) and improve medical care quality in Fujian province for China. Consecutive patients who were admitted and diagnosed with STEMI between January 2014 December 2018 were conducted at five regional representative hospitals in Fujian province, which included the Fujian Provincial Hospital,Longyan First Hospital, the affiliated hospital of putian university,the Second Affiliated Hospital of Fujian Medical University and Mindong Hospital of Ningde City.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7000
• Est. completion date: December 31, 2018
• Est. primary completion date: December 31, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• STEMI patients with symptom onset within 30 days

Exclusion Criteria:

Related Conditions & MeSH terms

• Infarction
• Myocardial Infarction
• ST Elevation Myocardial Infarction
• ST-segment Elevation Myocardial Infarction

Intervention

Other:
• treatment and outcome

Locations

Country	Name	City	State
China	Fujian Provincial	Fuzhou	Fujian

Sponsors (5)

Lead Sponsor	Collaborator
Yan-song Guo	Longyan City First Hospital, The Affiliated Hospital of Putian University, The MinDong Hospital of Ningde City, The Second Affiliated Hospital of Fujian Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	In-hospital mortality	all mortality,cardiovascular mortality	5years
Secondary	other in-hospital complications	recurrent myocardial infarction, target vessel revascularization,contrast-induced acute kidney injury,stroke,bleeding,and so on	5years
Secondary	MACEs for long-term follow up	mortality,stent restenosis, recurrent myocardial infarction, and target vessel revascularization,stroke,bleeding,and so on	1 year